Frontiers | Science News

Science News post list

9 news posts in Frontiers in Oncology

Health

06 Sep 2022

Bridging the medical gap in thoracic oncology – Prof Solange Peters and Dr Alfredo Addeo on the 4th International Lung Cancer Summit

Lung cancer, photomicrograph of small cell carcinoma As the scientific landscape across the field of oncology is constantly evolving, discussion around the latest treatment options in Thoracic Oncology is vital to help align on a common approach to the treatment of lung cancer – the leading cause of cancer-related death worldwide. Prof Solange Peters and Dr Alfredo Addeo are this year’s chairs of the 4th International Lung Cancer Summit (ILCS) held in Lausanne, Switzerland. Frontiers in Oncology has an ongoing relationship with the summit and are proud to be involved in supporting a platform for sharing the latest discoveries and advances towards the treatment of lung cancer. Prof Peters is the chair of Medical Oncology in the department of oncology at Lausanne University Hospital. She is also the chair of the European Society for Medical Oncology (ESMO) Women for Oncology Committee and the youngest ever ESMO president. Dr Addeo  is a consultant medical oncologist at the University Hospital of Geneva, Switzerland. He is also an active ESMO member and one of our Associate Editors in Frontiers in Oncology. Dr Addeo has been involved in leading multiple successful collections in our Thoracic Oncology section including ‘New Insights Into Targeting ALK in Patients […]

Featured news

17 Mar 2022

mRNA-based Covid-19 vaccines are safe for high-risk patients, shows study

By Conn Hastings, science writer Image: Shutterstock.com Patients with impaired immunity have faced a difficult predicament during the pandemic. Their condition places them at risk of severe Covid-19 complications, but until now, no-one knew if they were at higher risk of adverse side-effects following vaccination against Covid-19. A new study trialed two mRNA vaccines in such patients and found that they are safe and well tolerated. The results will help immunocompromised patients in making an informed choice about vaccination. Spare a thought for patients with impaired immunity during the Covid-19 pandemic. Their condition puts them at high risk of severe complications from Covid-19, but also creates uncertainty about the safety and effectiveness of the available vaccines that could protect them. A new study in Frontiers in Oncology helps to put this catch-22 situation to rest by finding that two popular mRNA-based vaccines are well tolerated by such high-risk patients. The trial found that the vaccines were safe and did not cause unexpected adverse events in a group of patients with various cancers, neurological, and rheumatological conditions that are associated with immunosuppression. The results will reassure vaccine-hesitant patients that the vaccines are safe, even for the immunocompromised.     ► Read original article► Download […]